Biomea Fusion to Become a Diabetes & Obesity Medicines Company
13 janv. 2025 09h00 HE
|
Biomea Fusion, Inc.
Icovamenib & BMF-650 (oral small molecule GLP-1) are the cornerstones of the metabolic franchiseBiomea preparing icovamenib for late-stage clinical development2025 corporate update to be presented...